Skip to content
10-K

Annual Report

SANGAMO THERAPEUTICS, INC SGMO

0001628280-26-022029

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 25, 2026 414.27M sh
Shares Diluted FY 2025 · Dec 31, 2025 280.19M sh
Shares Diluted FY 2025 · Dec 31, 2024 201.7M sh
Capex FY 2025 · Dec 31, 2025 $102K
Capex FY 2025 · Dec 31, 2024 $267K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$97.21M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$67.14M
Cash And Equivalents FY 2025 · Dec 31, 2025 $20.95M
Cash And Equivalents FY 2025 · Dec 31, 2024 $41.92M
Stockholders Equity FY 2025 · Dec 31, 2025 −$14.27M
Stockholders Equity FY 2025 · Dec 31, 2024 $22.77M
Stockholders Equity FY 2025 · Dec 31, 2023 $82.89M
Current Liabilities FY 2025 · Dec 31, 2025 $42.47M
Current Liabilities FY 2025 · Dec 31, 2024 $45.81M
Total Liabilities FY 2025 · Dec 31, 2025 $74.01M
Total Liabilities FY 2025 · Dec 31, 2024 $78.87M
Current Assets FY 2025 · Dec 31, 2025 $35.83M
Current Assets FY 2025 · Dec 31, 2024 $51.69M
Total Assets FY 2025 · Dec 31, 2025 $59.75M
Total Assets FY 2025 · Dec 31, 2024 $101.64M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.44
Eps Diluted FY 2025 · Dec 31, 2024 −$0.49
Eps Basic FY 2025 · Dec 31, 2025 −$0.44
Eps Basic FY 2025 · Dec 31, 2024 −$0.49
Sga Expense FY 2025 · Dec 31, 2025 $34.89M
Sga Expense FY 2025 · Dec 31, 2024 $44.73M
Rd Expense FY 2025 · Dec 31, 2025 $112.67M
Rd Expense FY 2025 · Dec 31, 2024 $111.52M
Net Income FY 2025 · Dec 31, 2025 −$122.93M
Net Income FY 2025 · Dec 31, 2024 −$97.94M
Operating Income FY 2025 · Dec 31, 2025 −$121.24M
Operating Income FY 2025 · Dec 31, 2024 −$103.97M
Revenue FY 2025 · Dec 31, 2025 $39.55M
Revenue FY 2025 · Dec 31, 2024 $57.8M